TickerTalks
Browse all tickers →
TickerTalks›$ABBV
ABABBV

AbbVie Inc.

$ABBV·$488B·Drug Manufacturers - General·Healthcare
$284.92+0.5%YTD+23.9%1Y+25.3%
Price updated 5m ago·X counts updated 5d ago
ABABBV
$ABBVAbbVie Inc.
$284.92+0.54%528 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $ABBV on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

528X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $ABBV's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-15

AbbVie presents at Wells Fargo's Boston healthcare conference with unusual fleet-activity clustering (8 Logan arrivals in 24 hours vs 16 in prior 3 years combined), fueling M&A speculation. Guggenheim's deep-dive on the DLL3 landscape ties ABBV in as a peer.

Read what X is saying about $ABBV

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ABBV — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

AbbVie's post-Humira pipeline is landing — the stock is at 92% of its 52-week range with Parkinson's and oncology both expanding.

AbbVie is the global biopharma that successfully managed the Humira patent cliff and is now compounding on its post-Humira pipeline — Skyrizi, Rinvoq, oncology, and now a Parkinson's pill. The stock has run to the top of its 52-week range on this quietly accelerating P&L.

  • Growth is accelerating: Q1 2026 revenue of $15B at +12% YoY after +10% in Q4 and +9% in Q3 — the ex-Humira franchise is now the dominant growth engine, with consensus revenue climbing to $73B in 2027 from $68B this year.
  • The pipeline keeps surprising: a new Parkinson's pill in late-stage development, DLL3 oncology peer-group inclusion, and the Wells Fargo conference activity (unusual fleet clustering flagged M&A chatter) — all adding to the compounding story.
  • Earnings beats are modest but consistent: 1-5% beats across four quarters — not dramatic, but the kind of cadence that lets 2027 consensus EPS of $16.41 hold up against a $262.82 stock (16x forward).

Oct 30 Q3 earnings with Skyrizi+Rinvoq combined growth above 50% and 2027 guide tracking consensus keeps the move going; a pipeline-safety signal or a cost-pressure print and the premium compresses.

Agrees with X sentimentX is bullish on the Wells Fargo conference fleet-clustering as M&A signal plus the DLL3 oncology peer-group framing — both directionally correct, and backed by the recent news flow (Parkinson's pill, drug-discount pilot). The crowd under-weights the 110x trailing P/E vs 16x forward distortion, which makes the setup look expensive on headline multiples.

What to watch: Oct 30 Q3 earnings — Skyrizi+Rinvoq combined growth above 50%, oncology pipeline progress, and any 2027 revenue guide tracking consensus $73B. Any pipeline safety signal is the asymmetric downside; a strong beat with raised guide extends the move.

On the calendar: 2026-10-30 — Q3 2026 earnings

Read the AI verdict on $ABBV

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Biopharmaceutical company with dominant immunology franchise (Humira, Skyrizi, Rinvoq) expanding into oncology and neuroscience.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $ABBV.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $ABBV

Partial — Biopharmaceutical company with dominant immunology franchise (Humira, Skyrizi, Rinvoq) expanding into oncology and neuroscience.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
110.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
10.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
27.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
68.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
70.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 31, 2026$3.65$3.61+1.1%
Q1 2026Apr 29, 2026$2.65$2.59+2.3%
Q4 2025Feb 4, 2026$2.71$2.65+2.3%
Q3 2025Oct 31, 2025$1.86$1.77+5.1%
Next earningsFri, Oct 30·consensus EPS $3.74

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.0B+12.4%71.9%31.6%$0.39$3.6B
Q4 FY25$16.6B+10.0%72.6%35.0%$1.02$4.9B
Q3 FY25$15.8B+9.1%66.4%12.1%$0.10$7.5B
Q2 FY25$15.4B+6.6%71.8%31.7%$0.53$4.9B

Forward consensus

5-year forecast · up to 20 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$67.6B$67.5B – $68.0B$14.02$13.90 – $14.2518
FY27$73.5B$71.9B – $74.9B$16.43$15.52 – $17.3818
FY28$78.9B$75.2B – $81.7B$17.85$15.30 – $21.2920
FY29$83.5B$81.5B – $84.9B$19.94$19.34 – $20.3710
FY30$85.2B$83.2B – $86.6B$21.01$20.38 – $21.4710

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.92%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+21.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.8B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.285-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 14Nicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICER32.7K sh$8.2M
+ 16 other (15 awards · 1 exempt) in window

See when $ABBV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeOct 158-K — Item 5.02: Officer or director change
8-KPress release / Reg FDSep 38-K — Item 7.01: Press release / Reg FD
AI summary

AbbVie Inc. filed an 8-K under Regulation FD (Item 7.01) disclosing a press release issued September 3, 2026. The body excerpt consists primarily of XBRL filing metadata rather than substantive press release content. The press release is attached as Exhibit 99.1 to the filing.

424B5Prospectus supplement (offering)Aug 6424B5
AI summary

ABBV filed a 424B5 prospectus supplement offering $500,000,000 aggregate principal in notes/securities. The offering includes 4.500% SENIOR. Net proceeds are approximately 9.93 billion. This is a live dilutive capital-markets transaction; size and pricing are material.

424B5Prospectus supplement (offering)Aug 4424B5
AI summary

AbbVie Inc. filed a preliminary 424B5 prospectus supplement for a multi-tranche debt offering of unsecured senior notes, including a floating rate tranche and multiple fixed-rate series across varying maturities; total offering size is redacted in this preliminary filing and will be set in the final supplement. Net proceeds are earmarked primarily to fund AbbVie's pending acquisition of Apogee Therapeutics, Inc., with remainder for general corporate purposes including debt repayment. The offering is not conditioned on completion of the Apogee deal, but certain tranches carry mandatory redemption provisions if the acquisition agreement is terminated. This is a significant capital raise tied to a transformative M&A transaction.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD
AI summary

AbbVie Inc. and Apogee Therapeutics, Inc. jointly announced on June 22, 2026 that they have entered into a definitive merger agreement for AbbVie to acquire Apogee, with AbbVie simultaneously presenting transaction details to investors under Reg FD. The Apogee Item 1.01 8-K confirms the merger consideration is $135.11 per share in cash, with all outstanding in-the-money options converted to cash at the spread. This is a transformative, highly material all-cash acquisition by a large-cap pharma significantly expanding its therapeutic pipeline via a full buyout of Apogee at a substantial premium.

8-KShareholder voteMay 128-K — Item 5.07: Shareholder vote
AI summary

AbbVie Inc. (ABBV) filed an 8-K reporting results of its annual shareholders' meeting held under Item 5.07. The filing is primarily XBRL-formatted tabular vote data with minimal narrative. Shareholders voted on routine matters including director elections, auditor ratification, and executive compensation. All standard proposals passed as expected at the well-established pharmaceutical company. Detailed vote tallies are attached as exhibits.

+ 11 other (4 earnings 8-Ks · 2 routine 8-Ks · 2 10-Qs · 1 11-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?fool.com·1d agoAbbVie Inc. $ABBV Position Reduced by Cliftonlarsonallen Wealth Advisors LLCdefenseworld.net·2d agoWhich Pharma Stock Looks More Attractive: Sanofi or AbbVie?zacks.com·2d agoAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Knowzacks.com·2d agoBlockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying247wallst.com·2d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OGN$LLY$NVO$PFE$JNJ$MRK$BMY$AMGN
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport